Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 12197215

Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Cancer Invest
Publication date
2002
First author
Edmonson JH

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Cancer Invest. 2002;20(5-6):853-4. doi: 10.1081/cnv-120002501.
    note
    Source null
    related pmid
    12197245
    relationship
    Comment in

Authors and identifiers

  1. name
    Edmonson JH
    type
    Author
  2. name
    Marks RS
    type
    Author
  3. name
    Buckner JC
    type
    Author
  4. name
    Mahoney MR
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Edmonson JH
    type
    Author
  2. name
    Marks RS
    type
    Author
  3. name
    Buckner JC
    type
    Author
  4. name
    Mahoney MR
    type
    Author
bibliography ids
  1. nci-bib-1a6686209afdbe9969090488
book metadata
content sha256
380d25988ccd570158c9cecf2eaecd606b852f73f589c4ecc039e0b8be133491
document type
citation
dois
  1. 10.1081/cnv-120002485
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:12197215
immutable id
pubmed:12197215@380d25988ccd570158c9cecf2eaecd606b852f73f589c4ecc039e0b8be133491
journal
abbreviation
Cancer Invest
issn electronic
Source null
issn print
0735-7907
issue
5-6
name
Cancer investigation
nlm unique id
8307154
pages
605-12
volume
20
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Cancer Invest. 2002;20(5-6):853-4. doi: 10.1081/cnv-120002501.
    note
    Source null
    related pmid
    12197245
    relationship
    Comment in
outcomes validated
false
pmid
12197215
provenance
batch id
ced7794d3512d3f45188
provider
NCBI PubMed ESummary
record sha256
4aa5bba1a76a863b88f4a04eaea9f05dedf67b69adc1de3fc9bafe8e10a37e3e
response sha256
782bfef1f051086807ee9551561575ae64b9ca1f941a87d5259ff83e5424435e
retrieved at
2026-09-09T23:45:46.208577+00:00
publication date
display
2002
precision
year
year
2002
publication types
  1. Clinical Trial
  2. Journal Article
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/12197215/
title
Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

Preserved source evidence · Not medical advice